Seyma Colakoglu Ozkaya

Dr. Seyma Colakoglu Ozkaya


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018
Verified
Journal Article
Closed access
SOSeyma Colakoglu Ozkaya
Seyma Colakoglu Ozkaya
TBTuran Bayhan
Turan Bayhan
BTBetul Tavil
Betul Tavil
EKEbru Yilmaz Keskin
Ebru Yilmaz Keskin
VCVolkan Cakir
Volkan Cakir
EBErgul Berber
Ergul Berber

14 June 2018 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
OBOğuzhan Fatih Baltacı
Oğuzhan Fatih Baltacı
SOSeyma Colakoglu Ozkaya
Seyma Colakoglu Ozkaya
GAGokce Gullu Amuran
Gokce Gullu Amuran
NANeslihan Aydın
Neslihan Aydın
MSMehmet Sarğın
Mehmet Sarğın
EBErgül Berber
Ergül Berber
Background/aim: MODY3 associated with HNF1A is the most common form of MODY and is clinically misdiagnosed as type 1 diabetes due to similar clinical symptoms. This study aimed to analyze the role of HNF1A-regulated miRNAs as a biomarker in the diagnosis of MODY3. Materials and methods: MIN6 cells were transfected with the HNF1A cDNA expression vector for overexpression or with siRNA specific to HNF1A to silence its expression. The HNF1A-regulated miRNAs were determined by RNA-Seq of the total RNA extract. Expressions of the candidate miRNAs in blood samples of MODY3, type 1 diabetes, and type 2 diabetes patients and in healthy subjects were compared statistically by Mann-Whitney U tests. Results: This study revealed the presence of 238 known HNF1A-regulated miRNAs in MIN6 cells. miR-129-1-3p, miR-200b-3p, and miR-378a-5p were selected as candidate miRNAs. The expression level of miR-378a-5p significantly decreased in type 2 diabetes and MODY3 patients, while miR-200b-3p expression was significantly decreased only in MODY3 patients. Conclusion: Although further studies with larger numbers of patients are required, this study demonstrated that the expression levels of miR-200b-3p and miR-378a-5p decrease in MODY3 patients and suggests that miR-200b-3p is an especially strong candidate to use clinically for selecting suspected MODY3 patients.

9 July 2024 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
KAKerem Abacar
Kerem Abacar
SOSeyma Colakoglu Ozkaya
Seyma Colakoglu Ozkaya
EBERHAN BIYIKLI
ERHAN BIYIKLI
Onur BuğdaycıOnur Buğdaycı
Onur Buğdaycı
MKMeltem Kurşun
Meltem Kurşun
PAPamir Atagündüz
Pamir Atagündüz

15 July 2025
Verified
Book Chapter
Closed access
PDF file
MAMisagh Asgari
Misagh Asgari
SOSeyma Colakoglu Ozkaya
Seyma Colakoglu Ozkaya
MAMehmet Pamir Atagündüz
Mehmet Pamir Atagündüz
Lavdie RadaLavdie Rada
Lavdie Rada

8 May 2026 in Rheumatology International
Verified
Journal Article
Closed access
AAAysegul Avcu
Aysegul Avcu
HGHalise Hande Gezer
Halise Hande Gezer
MDMehmet Tuncay Duruöz
Mehmet Tuncay Duruöz
EBEce Bıcakcı
Ece Bıcakcı
SOSeyma Colakoglu Ozkaya
Seyma Colakoglu Ozkaya
PAPamir Atagündüz
Pamir Atagündüz